Kailera Therapeutics IPO: Shares of obesity drugmaker start trading

Shares of biotech Kailera Therapeutics Inc. are available for trading on the Freedom client trading platform. The company’s lead asset, ribupatide, is part of the multibillion-dollar race for weight-loss drugs, a market expected to exceed $150 billion over the next decade. Later on Friday, the stock will start regular-session trading on the Nasdaq under the ticker symbol KLRA.

Kailera Therapeutics, a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized IPO on Nasdaq. The company sold about 39 million shares at $16 per share – the top of the marketed range. Based on the IPO price, Kailera is worth about $2 billion, Bloomberg reported.

The offering was led by JPMorgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and William Blair. The underwriters have a 30-day option to purchase up to 5.8 million additional shares at the IPO price.

Existing investors, including Bain Capital Private Equity, Bain Capital Life Sciences, and Qatar Investment Authority, indicated interest in buying up to $225 million of stock in aggregate at the IPO price, Reuters wrote.

Kailera said it plans to use the IPO proceeds to fund the development of its drug pipeline.

Kailera Therapeutics is a clinical-stage biotechnology company founded in 2024, developing GLP-1-based treatments for obesity. It is advancing four drug candidates, including a once-weekly injectable and a once-daily oral tablet. The company’s lead candidate, ribupatide, is a GLP-1/GIP receptor dual agonist currently in phase III trials. It targets the same class of therapies as blockbuster drugs from Eli Lilly and Novo Nordisk.

Kailera licensed its portfolio from China-based Jiangsu Hengrui Pharmaceuticals and launched with $400 million in initial funding, BioSpace writes. In October, the company raised an additional $600 million in a funding round.

All four drugs in the company’s portfolio are in clinical-stage trials. The lead candidate, ribupatide, is currently being evaluated in phase III studies. It is a once-weekly injectable targeting both GLP-1 and GIP receptors, helping regulate insulin production and metabolism. The same mechanism underpins Zepbound from Eli Lilly and Company. Kailera states that its drug has the potential to compete with it on both efficacy and tolerability. At the same time, the company is developing an oral formulation of ribupatide for once-daily use.

Kailera’s IPO is the first in the obesity treatment space since the listing of Metsera in January 2025, Axios reported. Later in autumn of last year, Metsera became the subject of a bidding war between Pfizer and Novo Nordisk. Pfizer ultimately prevailed, paying nearly $10 billion.

IPO expert Donovan Jones said the company’s financial profile is typical for a clinical-stage biopharma, with no revenue and significant R&D and other expenses. As of December 31, Kailera had $546 million in cash and liquid assets and $56.4 million in liabilities, with no debt, providing a substantial liquidity cushion to continue development. However, additional funding will be required to reach commercialization.

Kailera is obligated to make clinical and regulatory milestone payments of up to $200 million to Jiangsu Hengrui Pharmaceuticals, as well as commercial milestone payments of up to $5.7 billion depending on the success of its drugs, he said.

Jones said key factors supporting the company include strong capitalization, a solid investor base, positive clinical data, an experienced management team, and significant market potential. The global market was estimated at $63 billion in 2025 and could reach $254 billion by 2034, he said.

The key question is whether ribupatide can demonstrate meaningfully better results versus competing drugs. Otherwise, market entry could be constrained by dominant players, he warned.

According to Freedom Finance analyst Alem Bektemirov, the global GLP-1 drug market could grow to $157.5 billion by 2035. He also pointed to risks if Kailera fails to secure additional capital, which could delay or halt development programs, as well as the possibility that the drugs may not receive regulatory approval.

Bektemirov sets a target price of $22.20 per share, implying upside of 38% versus the IPO price.

_______________________

Freedom clients will be able to trade Kailera Therapeutics shares before the start of the main U.S. session. Premarket trading will open 2-3 hours early, at 15:30-16:30 Astana time. Investors can participate by selecting the symbol KLRA on the Freedom platform.